A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY EVALUATING THE EFFICACY AND SAFETY OF PEMBROLIZUMAB PLUS PLATINUM-BASED DOUBLET CHEMOTHERAPY WITH OR WITHOUT CANAKINUMAB AS FIRST LINE THERAPY FOR LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS AND SQUAMOUS NON-SMALL CELL LUNG CANCER SUBJECTS (CANOPY-1)

Registry ID

CACZ885U2301

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2020-04-07

Completion date

2021-06-03

Last update

2018-11-22

Conditions

• NON-SQUAMOUS/SQUAMOUS NSCLC

Related clinical trials

• BEAMION PANTUMOR-1: A PHASE II, MULTICENTRE, MULTICOHORT, OPEN LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZONGERTINIB (BI 1810631) FOR THE TREATMENT OF SELECTED HER2-MUTATED OR OVEREXPRESSED/AMPLIFIED SOLID TUMOURS
• A PHASE III, RANDOMISED, OPEN-LABEL, GLOBAL STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) IN COMBINATION WITH RILVEGOSTOMIG (AZD2936) OR RILVEGOSTOMIG MONOTHERAPY VERSUS PEMBROLIZUMAB MONOTHERAPY FOR THE FIRST-LINE TREATMENT OF PARTICIPANTS WITH LOCALLY-ADVANCED OR METASTATIC NON-SQUAMOUS NSCLC WITH HIGH PD-L1 EXPRESSION (TC ¿ 50%) AND WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG10)
• A RANDOMIZED PHASE 3 STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) AND PEMBROLIZUMAB, WITH OR WITHOUT PLATINUM CHEMOTHERAPY, IN SUBJECTS WITH NO PRIOR THERAPY FOR ADVANCED OR METASTATIC PD-L1 TPS <50% NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG07)

View on source registry